At 12 weeks postinjection, we do not observe alterations in the distribution of total or phosphorylated (Ser129) α-synuclein (Fig. 8), a major component of Lewy body pathology in PD and other α-synucleinopathies (3,18), following human VPS35 expression. Here, VPS35 is linked to synucleinopathy.